Incyte CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

10 Feb 2026

INCY

10-K: Incyte Soars on Strong 2025 Earnings, Pipeline Wins

Incyte Corporation reported a significant surge in net income and total revenues for 2025, driven by robust product sales and key clinical advancements, despite looming patent expirations for its flagship drug.

NASDAQ

10 Feb 2025

INCY

Incyte CORP

10-K: Incyte's 2024 Annual Report: Revenue Growth Driven by Key Products Amidst Strategic Pipeline Review

Incyte reports increased revenue driven by JAKAFI and OPZELURA, alongside strategic pipeline adjustments and a significant share repurchase program in its 2024 annual report.

NASDAQ

16 Feb 2024

INCY

Incyte CORP

10-K/A: Incyte Corporation Files Amended 10-K to Correct Recoupment Policy Exhibit

Incyte Corporation filed an amendment to its annual report on Form 10-K to correct an administrative error related to the company's policy for recoupment of erroneously awarded compensation.

NASDAQ

13 Feb 2024

INCY

Incyte CORP

10-K: Incyte Corporation Reports 2023 Financial Results, Highlights Growth in Key Therapeutic Areas

Incyte Corporation's 2023 annual report reveals a strong financial performance, driven by increased product sales and strategic collaborations.